Hansoh Pharma Licenses Two ADC Candidates, HS-20089 and HS-20093, to GSK in Major Global Deals
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
| Lead Rise Individual Thigh |
Name | Relevant | Price Change |
|---|---|---|---|
| Zhejiang Zhenyuan | Research Report Capital Flow | 4.04% | |
| Sinopharm Accord | Research Report Cash Flow | 0.77% | |
| Yifeng Pharmacy | Research Report Cash Flow | 0.13% | |
| KaiKai Industrial | Research Report Cash Flow | -0.09% | |
| Click to view all>> | |||
| Resources Gold Flow Entry |
Name | Relevant | Net Inflow (Million) |
|---|---|---|---|
| Yifeng Pharmacy | Research Report Cash Flow | 399.03 | |
| Tyencon | Research Report Cash Flow | 268.03 | |
| Chongqing Pharmaceutical Holdings | Research Report Cash Flow | 193.99 | |
| People's Tongtai | Research Report Cash Flow | 115.76 | |
| Click to view all>> | |||
Recently, Hansoh Pharma has successively licensed 2 ADC drugs to GSK:
(1) GSK will obtain an exclusive global license (excluding mainland China, Hong Kong, Macao, and Taiwan) to develop, manufacture, and commercialize HS-20089. This product is a novel B7-H4-targeted antibody-drug conjugate (ADC) with a topoisomerase inhibitor (TOPOi) as its payload. Hansoh Pharma will receive an upfront payment of $85 million and is eligible to receive milestone payments of up to $1.485 billion upon the achievement of related events for this product.
(2) GSK will obtain an exclusive global license (excluding mainland China, Hong Kong, Macao, and Taiwan) to develop, manufacture, and commercialize HS-20093. This product is a novel B7-H3-targeted antibody-drug conjugate (ADC) with a topoisomerase inhibitor (TOPOi) as its payload. Hansoh Pharma will receive an upfront payment of $185 million and is eligible to receive milestone payments of up to $1.525 billion upon the achievement of related events for this product.
China-produced ADCs are gaining significant overseas momentum, with notable platform value. ADC drugs represent the organic integration of antibodies and their conjugates, and we believe that China-based manufacturers can achieve relative competitiveness by leveraging the engineer红利. The overseas expansion of ADC drugs by Hansoh Pharma and others demonstrates the recognition of China's ADC drug platforms.
It is recommended to focus on: Hengrui Medicine, Hansoh Pharma, Baili Tianheng, Kelun Botai Bio-B, etc.
Risk Warning: Risk of review failure, risk of deteriorating competitive landscape, risk of valuation fluctuation.